Post-approval study approaches
Phase IV
Historically, Phase IV studies were considered the last step in the classical model of phased drug development. In paediatric drug development, this post-approval or post-marketing Phase IV commitment may require sponsors to conduct additional studies in younger age groups or to monitor for rare adverse events in the general population. Registry-based and observational study designs are increasingly used for Phase IV paediatric studies but may also include pragmatic randomized controlled trials (Box 10) to evaluate comparative effectiveness or context and use of new medicines to existing medicines in routine care settings. See the section on pharmacovigilance and the use of real-world data in post-approval research on the safety and effectiveness of newly introduced paediatric medicines in routine care settings.
Phase IV studies are also critical to including children who fall into subgroups that were previously excluded from safety and efficacy trials, such as children with comorbidities or coinfections or in age groups not included in trials. The study of off-label use can inform changes to licensing and guidelines on use.
Strategy Trials
Strategy trials are designed to answer questions about how to develop, deliver or evaluate a biomedical intervention in the post-marketing period. They have also been used for comparing effectiveness between approved medicines for the same indication. A strategy trial might compare different approaches to identifying and enrolling children with a condition, different durations of treatment or different diagnostic or monitoring strategies.
However, historically, strategy trials were designed within controlled high-resource settings, therefore not reflecting real-world conditions and use. Limitations from strategy trials contributed to integrating innovative implementation science methods in trial research, including pragmatic designs, to optimize generalizability and generate real-world evidence.
| Box 10. Pragmatic trials |
|---|
A pragmatic trial evaluates an intervention under the conditions in which they are routinely delivered in real-world health-care settings. They are designed to determine whether an intervention works at scale in clinical practice and how it performs across diverse populations and health systems. They may compare different established treatments, diagnostic approaches, care pathways or service-delivery models using routine clinical settings and existing data sources such as medical records. In paediatrics, they can help address questions that are difficult to answer through conventional trials, including how interventions perform across different ages, levels of health care and resource settings. |
Implementation research
Implementation research approaches or methods aim to answer questions about what medicines work, for whom, under what circumstances and how can they be delivered effectively. When applied effectively, these approaches can provide complementary evidence to investigational new drug trials and are essential for understanding the full pathway from evidence generation to effective, equitable use of paediatric interventions in routine practice. Implementation research typically takes place in the post-approval phase, although there are some efforts to embed implementation research approaches earlier in the clinical development life cycle.
In the pre-approval phase, implementation science methods can be embedded alongside traditional efficacy and safety trials to generate early evidence on feasibility, acceptability and delivery: for example, assessing the caregiver and provider acceptability of a new paediatric formulation, feasibility of dosing and administration in real-world clinical settings or the health system readiness required to support roll-out.
In the post-approval phase, implementation research shifts toward understanding uptake, adherence and equity of access once a medicine moves into routine use, addressing questions such as how well the product performs outside the controlled trial environment, what barriers limit reach to underserved or hard-to-reach paediatric populations and how delivery strategies can be adapted or scaled across diverse health systems. In a hybrid effectiveness-implementation approach, implementation strategies can be tested in parallel with effectiveness studies on long-term safety and quality of life following novel treatments in real-world settings.
Implementation science helps to close the gap between a medicine being proven safe and efficacious and it being reliably, equitably and sustainably delivered to the children who need it.